Loading clinical trials...
Loading clinical trials...
A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants
Conditions
Interventions
MK-8558
Locations
2
Germany
Charite Research Organisation GmbH ( Site 0001)
Berlin, Germany
Matei Bals Infectious Diseases Institute ( Site 0002)
Bucharest, Bucharest, Romania
Start Date
April 26, 2019
Primary Completion Date
May 29, 2020
Completion Date
May 29, 2020
Last Updated
May 28, 2021
NCT06660498
NCT06602622
NCT06185452
NCT06902038
NCT04568603
NCT01511809
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions